Title: George J. Fennington: Innovator in Biologic Manufacturing Processes
Introduction
George J. Fennington is an accomplished inventor based in the United States. He has made significant contributions to the field of biologic manufacturing, particularly through his innovative methods for purifying and inducing cells. His work focuses on enhancing the efficiency and safety of primary cell derived biologics.
Latest Patents
George J. Fennington holds a notable patent titled "Primary Cell Derived Biologic Modified Manufacturing Process." This patent outlines a highly efficient method for creating primary cell derived biologics by purifying mononuclear cells (MNCs) using an automated cell processor. The process involves loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging to obtain purified MNCs. The MNCs are then stored in a closed sterile bag system and stimulated with phytohemagglutinin (PHA) or other mitogens, along with ciprofloxacin, in a scalable cell culture device. The method emphasizes the importance of preventing contamination and ensuring the purity of the resulting biologic.
Career Highlights
George J. Fennington is currently associated with Irx Therapeutics, Inc., where he continues to develop and refine his innovative processes. His work has been instrumental in advancing the field of biologic manufacturing, particularly in the context of cell therapy and regenerative medicine. Despite having no patents listed under his name, his contributions to the industry are noteworthy.
Collaborations
George collaborates with Harvey J. Brandwein, leveraging their combined expertise to push the boundaries of biologic manufacturing. Their partnership exemplifies the collaborative spirit often found in research and development.
Conclusion
George J. Fennington is a key figure in the innovation of biologic manufacturing processes. His work in developing efficient methods for purifying and inducing cells has the potential to significantly impact the field of regenerative medicine.